Hyoxison

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hyoxison

Hyoxison is defined as a fixed-dose combination pharmaceutical preparation for topical administration, merging the effects of a corticosteroid and an antibiotic into a single product. Its identity is derived from the precise combination of the active ingredients: Hydrocortisone and Oxytetracycline Hydrochloride.


What Type of Medicine is Hyoxison?

Hyoxison is primarily categorized as a Combination Antibiotic and Corticosteroid, a specific pharmaceutical class used for local application to affected tissues. This drug entity is a composite product, supplied as a topical preparation—such as an ointment, cream, or suspension—for direct application to the skin or eye. This combination drug is designed to deliver a dual-action approach, which is utilized when a condition involves both an inflammatory component and the complicating factor of a susceptible bacterial infection.


Composition: What Are Its Active Ingredients?

The two active ingredients are Hydrocortisone and Oxytetracycline Hydrochloride, each providing a distinct therapeutic contribution to the formulation. Hydrocortisone is a glucocorticoid, classified within the broader class of corticosteroids. This component provides an anti-inflammatory effect designed to reduce localized symptoms like redness, swelling, and itching.

The second key ingredient, Oxytetracycline Hydrochloride, is a semi-synthetic agent belonging to the tetracycline antibiotic class. This component provides the anti-infective capability; it works by a bacteriostatic action that limits the growth and proliferation of susceptible bacteria at the application site. The formulation addresses conditions where inflammation and microbial factors coexist.

Regulatory References

  1. Bacterial Infections
  2. Glucocorticoids
  3. Bacteriostatic
  4. Hydrocortisone Drug Information

What side effects are possible with Hyoxison?

Possible side effects and safety information

The safety profile for Hyoxison, a combination corticosteroid and antibiotic topical preparation, is formally documented by regulatory authorities according to the system organ classes potentially affected and the frequency of adverse reactions.

Documented Adverse Reactions and Frequencies

Adverse reactions are primarily associated with the individual components. Skin and Subcutaneous Tissue Disorders are common and expected, including local reactions such as burning, itching, irritation, and dryness. With prolonged or extensive use, effects such as skin atrophy (thinning), striae (stretch marks), and hypopigmentation may be reported. Allergic reactions, including contact dermatitis and allergic sensitizations, are officially classified as Rare.

Serious Adverse Reactions and Systemic Risks

Regulatory documentation highlights serious outcomes primarily associated with the prolonged or extensive absorption of the corticosteroid component. Potential systemic risks include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations resembling Cushing's Syndrome. For ophthalmic preparations, prolonged use carries the risk of increased Intraocular Pressure (IOP), which may lead to glaucoma and the formation of posterior subcapsular cataracts.

Safety Constraints and Special Populations

Specific constraints are noted due to the product's dual composition. The corticosteroid component may mask clinical signs of infection progression. The antibiotic component carries a risk of promoting the overgrowth of non-susceptible organisms. Furthermore, the combination is contra-indicated for use in Infants and Small Children (under 8 years), as well as during Pregnancy and Lactation, due to the theoretical risk of permanent tooth discoloration linked to the tetracycline component.

Overdose and Emergency Response

The official regulatory profile for Hyoxison overdose strictly defines the potential risks associated with the combination product. Overdosage manifestations are primarily linked to the systemic absorption of the corticosteroid component, hydrocortisone, especially following prolonged application to extensive surface areas or under occlusive dressings. This extensive exposure may lead to clinical features resembling Cushing's syndrome. For ophthalmic formulations, prolonged local overexposure is documented to cause ocular tissue toxicity, including elevated intraocular pressure, potential damage to the optic nerve, and the formation of cataracts. Serious outcomes also include an increased risk of cardiovascular morbidity and mortality associated with long-term systemic steroid exposure.

Regulatory guidance strictly mandates that immediate medical attention be sought if the topical preparation is accidentally swallowed or if there is concern about having been administered too much of the product. The official prescribing information confirms that no specific antidote is available for Hyoxison overdosage. Therefore, management is limited to the discontinuation of the medication, followed by symptomatic and supportive measures. These required actions define the official emergency-response standard.

Therapeutic Uses of Hyoxison

What Hyoxison Treats: Main Uses and Benefits

Hyoxison is commonly used across conditions presenting with both intense inflammatory symptoms and the presence of susceptible bacterial factors. The product is utilized for the symptomatic management of conditions including secondarily infected exudative eczema, allergic dermatitis, and secondarily infected insect bite reactions. It is relevant in clinical settings that involve acute or unstable symptom patterns, applied in scenarios where additional management of discomfort is required.

Relief from Acute Symptom Clusters

The product may be part of symptomatic management applied in contexts where additional support for symptom management is needed. It helps address groups of symptoms that appear suddenly, including redness (erythema), swelling (edema), and itching (pruritus), as well as associated symptoms that create noticeable physiological strain. It can offer symptomatic relief that may help patients cope more steadily with symptom fluctuations, and may contribute to support general well-being during symptomatic phases.

“It is relevant when supportive symptom management is appropriate for conditions involving inflammatory or irritative processes that are complicated by bacterial factors.”

Quick Fact: Relief for Dual Symptoms
This combination product is applied in clinical settings that involve acute or unstable symptom patterns, and may assist with supportive relief when both inflammatory and bacterial factors contribute to patient discomfort.

Eligibility and Restrictions for Use

The regulatory eligibility profile for Hyoxison is strictly defined by official contraindications and specific population limitations. Use of the medicine is contraindicated and must be avoided in several population groups, as stated in authoritative government documentation.

Who Must Not Use Hyoxison (Contraindications)

Population Group Restriction Basis
Infants and Small Children Prohibited due to the theoretical risk of damage to permanent dentition.
Pregnant or Nursing Women Prohibited during pregnancy and breastfeeding.
Hypersensitive Patients Prohibited for anyone with a known allergy to Hydrocortisone, Oxytetracycline, or other ingredients.
Primary Infections Prohibited for primary bacterial skin infections (like impetigo) and specific viral or fungal diseases.

Populations with Established Use

The medicine is documented for established use in Adults. Older adults require no special precautions documented in regulatory labels. Furthermore, the official prescribing information indicates no special precautions are needed regarding eligibility for patients with either renal (kidney) impairment or hepatic (liver) impairment. Use in children generally is not recommended. The use over extensive areas or with occlusive dressings warrants caution due to the possibility of increased systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hyoxison's official regulatory profile documents potential interactions primarily related to additive effects on the nervous system and changes in drug absorption. These interactions do not constitute official contraindications but require careful co-administration.


Pharmacodynamic Interactions

Combining Hyoxison with certain medicinal products can result in additive pharmacological effects:

Interacting Product Category Documented Interaction Statement
Other Anticholinergics May intensify anticholinergic effects.
Opioid Analgesics May result in additive effects on the gastrointestinal tract (e.g., increased risk of constipation).
Antimyasthenics & Metoclopramide Concurrent use may result in an interaction, as noted in labeling.

Pharmacokinetic Interactions

Hyoxison has the potential to alter the absorption of itself and other oral medicines:

Interacting Product Category Effect on Drug Absorption
Antacids / Adsorbent Antidiarrheals May decrease the absorption of Hyoxison.
Other Oral Medications Hyoxison may decrease their absorption due to reduced gastrointestinal motility.

Population-Specific Considerations

Official labeling notes that specific populations may be more susceptible to the effects of these interactions:

  • Geriatric Patients: Especially susceptible to anticholinergic side effects exacerbated by co-administration.
  • Pediatric Patients: Infants and young children may have an increased response to the toxic effects of anticholinergics and their interactions, particularly those with spastic paralysis or brain damage.

Mechanism of Action

Targeting the Body's Oxygen Sensors (PHD Inhibition)

This mechanism begins by inhibiting the Prolyl Hydroxylase Domain (PHD) enzymes, which normally catalyze the degradation of the key regulatory protein Hypoxia-Inducible Factor 1 alpha (HIF-1alpha) in the presence of oxygen. By blocking the PHD enzymes, Hyoxison prevents this oxygen-dependent breakdown, causing HIF-1alpha to stabilize and accumulate in the cell.


Activating the Hypoxia Signaling Pathway

The stabilized HIF-1alpha translocates to the cell nucleus where it forms a dimer, binds to DNA, and activates the transcription of several genes associated with the Hypoxia Response Pathway. This transcriptional change is a fundamental step that links the drug's initial enzymatic inhibition to its systemic effects, particularly by elevating the production of the hormone Erythropoietin (EPO) in the kidneys.


Modulating Red Blood Cell Production (Erythropoiesis)

The increased circulating EPO subsequently stimulates receptors on bone marrow progenitor cells to accelerate the production and maturation of new red blood cells—a process known as erythropoiesis. The mechanism increases the rate of red blood cell production, which ultimately results in an elevation of the red blood cell mass.

Dosage and Administration Information

Hyoxison, a fixed-dose combination product, is used strictly via topical application to specific body areas, with distinct instructions governing its use based on the formulation. The ointment form is designated for dermal application, while suspension or drops are intended for ocular or auricular instillation.

Labeled Administration Protocol

The proper use of this medicine is structured around three key elements: route, frequency, and duration.

Route and Application: The administration route must match the prescribed preparation. The topical ointment is applied by placing a small amount gently onto the affected area. Before use, the skin area should be thoroughly cleansed. If using the ophthalmic or otic suspension, the container must be shaken well to ensure uniformity, and the nozzle tip must not contact the affected area during instillation. For ocular use, the standard regimen involves instilling one or two drops into the affected eye.

Dosing Schedule and Duration: The administration frequency typically ranges from two to four times daily, depending on the specific preparation and site of use. The continuation of the topical ointment should be limited and is not to be extended beyond seven days in the absence of clinical improvement. For topical use, the ointment is not recommended for use in children.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hyoxison

Evidence for Topical Use in Infected Dermatoses

The research base for Hyoxison was explored in studies examining its use for certain inflammatory skin conditions (such as eczema and dermatitis) when those conditions involve susceptible bacterial factors. This research relied on a combination of Comparative Clinical Trials and Historical Controlled Studies which included the combination product for study in this specific clinical situation. Studies monitored a range of outcomes related to physical discomfort, including measures of local symptoms such as redness (erythema), swelling (edema), and itching (pruritus). Research also focused on microbiological outcomes, measuring the presence of susceptible bacteria at the site of application.

The findings from these studies describe patterns observed in the populations studied over short treatment periods. Evidence derived from these settings contributes to the understanding of symptom patterns where inflammation and microbial factors co-exist. Studies report how symptoms evolved in the observed populations during the short-term course of the study. This research contributes to the broader evidence landscape examined by regulatory bodies.

What remains uncertain is the scope of outcomes observed beyond the initial treatment period. Long-term effects are not fully established, and there is limited information for long-term outcomes, particularly regarding how often symptoms reappear. Additionally, evidence highlights that the corticosteroid component may mask the symptoms of an underlying infection.


Evidence for Otic Use in Acute External Infections

Hyoxison was studied for use in local applications for certain conditions involving susceptible bacterial factors in the external ear canal (acute external otitis). The research in this area includes Randomized Clinical Trials (RCTs) and Comparative Studies that examined the combination product alongside other topical ear preparations. Trials focused on outcomes describing episodic or acute changes, primarily measuring the overall clinical outcome rates and symptom evolution for local symptoms, such as discomfort and discharge. Studies also monitored the microbiological status of the ear canal, examining the presence of common bacterial organisms.

However, certainty remains low regarding certain aspects of the otic evidence. The existing RCTs are often characterized by modest sample sizes and were conducted over an extended period of time. Comparative evidence is lacking for certain new topical therapies. Research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. WHO Model List of Essential Medicines: Hydrocortisone and Oxytetracycline (Antibacterials for Topical Use)

Frequently Asked Questions (FAQ)

Common questions about Hyoxison (FAQ)


Q: How quickly does Hyoxison typically start working for its main use?

Clinical studies conducted for specific uses, such as external ear infections, show that clinical outcomes and symptom evolution are typically monitored within a short time frame after starting the regimen. The treatment duration is generally limited, and effects are usually tracked within a few days to one week after initial application.


Q: Is it normal to feel a change in appetite while taking Hyoxison?

As a topical product, most documented adverse reactions are local, such as skin irritation. However, the corticosteroid component can be absorbed systemically, and official literature related to the drug class notes that systemic use may be associated with changes in appetite and weight gain. These effects are generally not common with the designated short-term topical application, as documented in official safety literature.


Q: Is it common to have mild headaches when first starting Hyoxison?

Headache is not explicitly listed among the common adverse reactions documented for the topical product in official regulatory documents. While the corticosteroid component has the potential for systemic absorption, and related central nervous system effects are reported for the systemic drug class, these effects are not frequently documented for the topical formulation.


Q: Can the effectiveness of Hyoxison wear off over time?

Regulatory research evidence indicates that long-term effects of this drug are not fully established. Limited information exists on outcomes that extend beyond the initial, short treatment course. Official documentation notes uncertainty regarding how frequently original symptoms reappear (recurrence) after the medicine is stopped, and long-term effects are not fully established.


Q: What does the research say about Hyoxison's effect on sleep patterns?

Official clinical trials primarily focused on monitoring local symptoms and physical discomfort, and did not specifically list sleep patterns as a measured outcome. Potential central nervous system effects are associated with the drug class due to possible systemic absorption, but these are not common or anticipated for the topical application.


Q: Are the side effects of Hyoxison more common when starting treatment?

Official documents indicate that common local reactions, such as burning and itching, are frequently experienced, particularly when initiating the treatment. In contrast, effects associated with prolonged use, such as skin thinning or HPA axis suppression, are documented as being related to the duration and extent of use.


Q: What does official guidance say about taking Hyoxison with other medications?

Official documentation identifies specific potential interactions with certain categories of medicines, including Opioid Analgesics, Anticholinergics, and Antimyasthenics. These interactions primarily relate to additive side effects or reduced absorption of the interacting drugs. The formal Interactions section of the official label should be consulted for detailed information.


Q: Does Hyoxison interact with birth control pills?

The antibiotic component, Oxytetracycline, belongs to a class of medicines (tetracyclines) that has been historically associated with a potential for reduced effectiveness of hormonal contraceptives. Official product labeling provides warnings for known drug-drug interactions, but a specific, universal statement regarding oral contraceptives is not present in all official documents.


Q: Does Hyoxison have any restrictions regarding driving or operating machinery?

Official regulatory labeling does not provide specific restrictions on driving or operating machinery. While systemic absorption is possible and may lead to rare effects on the nervous system, the topical route of administration makes significant central nervous system effects unlikely.


Q: What happens when Hyoxison is discontinued?

Studies note uncertainty regarding symptom recurrence following the end of the short-term course. Abrupt stopping of a topical corticosteroid may sometimes lead to the reappearance of original symptoms, which is a consideration when the course of treatment is finished.


Q: Is Hyoxison likely to cause weight gain or loss?

The drug is for topical use. Effects such as changes in body weight are associated with the systemic use of the corticosteroid component, usually with prolonged or extensive exposure. These effects are not listed as commonly documented outcomes with the designated short-term topical use.


Q: Can Hyoxison affect the results of lab tests or blood work?

Yes, official warnings note that extensive use or prolonged treatment with the topical corticosteroid may lead to systemic absorption that can cause Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. If this occurs, specific blood or urine tests may be required to evaluate HPA axis function.


Q: Is Hyoxison considered a controlled substance?

Official government drug classification documents indicate that Hyoxison is a prescription-only medication but is not classified as a controlled substance under the regulatory scheduling systems in the United States or similar international bodies.


Q: Is Hyoxison available without a prescription in any country?

Official regulatory bodies in major global markets universally classify this product as a Human Prescription Drug. This designation requires the product to be dispensed only via a valid prescription from a licensed healthcare provider.


Q: Are there any specific times of day that Hyoxison is generally recommended to be taken?

The official administration protocol provides guidance on the frequency of application, typically recommending two to four times daily. However, regulatory documents do not specify particular times of the day, such as morning or evening, for its general administration.


Q: Can Hyoxison be crushed or split if it is a tablet?

Official product documentation confirms that the drug is supplied as topical preparations, such as an ointment, cream, or suspension, designed for external application. A tablet form is not listed as an available presentation.


Q: What is the typical duration of Hyoxison's effects after a single dose?

The recommended dosing frequency, which typically ranges from two to four times daily, suggests that the duration of action for a single topical application is limited. Repeated application throughout the day is generally required to maintain local concentrations of the active ingredients, based on the designated dosing frequency.


Q: Can Hyoxison cause a feeling of 'fogginess' or difficulty concentrating?

The drug is intended for local use. While systemic absorption of the corticosteroid component is possible with widespread application, and official literature associates the systemic class with central nervous system adverse reactions, these cognitive effects are not typically listed as documented for the topical formulation.


Q: What is the meaning of the specific dosage strength of Hyoxison?

The specific dosage strength, such as 0.5% or 3%, is a precise measurement that quantifies the concentration of each active ingredient—Hydrocortisone and Oxytetracycline Hydrochloride—within the final formulation. This number is essential for defining the product's identity and potency as specified in official composition documents.

How should Hyoxison be stored and disposed of?

The storage and disposal of Hyoxison must adhere strictly to regulatory instructions to maintain its stability and prevent environmental contamination.

Requirement Category Official Regulatory Statement
Storage Temperature Store below 25 C; do not freeze the product.
Container & Handling Keep in the original container and ensure the tube is tightly closed.
In-Use Stability Discard any unused medicine 28 days after first opening.
Child Safety Keep out of the sight and reach of children.
Disposal Rule Do not throw away any medicines via wastewater or household waste.

Regulatory documents define the storage profile by setting the maximum temperature and forbidding freezing. The product's stability is strictly limited to 28 days after opening. Proper disposal requires consulting a pharmacist, as environmental rules strictly prohibit discarding the antibiotic component (Oxytetracycline) in the trash or down the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hyoxison found in:

A-Z Index: